Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68-Ga-RM2 PET/MRI in ER+ Breast Cancer
NCT03831711Phase 2Completed
- Sponsor
- Andrei Iagaru
- Start
- Mar 2019
- Primary completion
- Nov 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-DOTA-Bombesin in estrogen receptor-positive breast cancer (ER+), sponsored by Andrei Iagaru. Primary endpoint: Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI up to 2 hours. Started Mar 2019; status: completed.
02
Drugs
68Ga-DOTA-Bombesin
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT03831711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831711.